Research progress of inflammatory cytokines in the diagnosis and treatment of amyotrophic lateral sclerosis

doi:10.16352/j.issn.1001-6325.2022.06.012

Abstract

Abstract: Amyotrophic lateral sclerosis (ALS) is a multifactor, multiple genes disease which involving a variety of mechanisms. Neuroinflammatory response is one of the mechanisms. Many inflammatory cytokines are involved. It may be used in clinic as biomarkers and therapeutic targets. Many proteins encoded by mutant genes can damage the function of immune system, lead to immune dysfunction and drive the inflammatory response of central nervous system and peripheral immune system. There are many kinds of inflammatory cytokines with great diversification in their levels which influenced by the stage, type and comorbidity of the disease, the results are not consistent at present, and there is no single inflammatory cytokine identified as a specific marker. Inflammatory cytokines have a certain prospect as therapeutic monitoring markers and targets.

Key words: amyotrophic lateral sclerosis, gene variant, inflammatory cytokines

CLC Number:

R746.4

LI Xiao-guang, YANG Lu, LIU Xu-dong, JIA Xin-miao, CHENG Yan-fei, CUI Li-ying. Research progress of inflammatory cytokines in the diagnosis and treatment of amyotrophic lateral sclerosis[J]. Basic & Clinical Medicine, 2022, 42(6): 964-968.

References

[1] Beers DR, Appel SH. Immune dysregulation in amyotro-phic lateral sclerosis: mechanisms and emerging therapies[J]. Lancet Neurol,2019,18:211-220.
[2] Brodovitch A, Boucraut J, Delmont E, et al. Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS[J]. Sci Rep, 2021, 11:703. doi: 10.1038/s41598-020-80370-6.
[3] Rolfes L, Schulte-Mecklenbeck A, Schreiber S, et al. Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation[J]. Brain Commun, 2021, 3:fcab157. doi: 10.1093/braincomms/fcab157.
[4] Lu CH, Allen K, Oei F, et al. Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis[J]. Neurol Neuroimmunol Neuroinflamm, 2016,3:e244. doi: 10.1212/NXI.0000000000000244.
[5] Du Y, Zhao W, Thonhoff JR, et al. Increased activation ability of monocytes from ALS patients[J]. Exp Neurol, 2020,328:113259. doi: 10.1016/j.expneurol.2020.113259.
[6] Kurashige T, Kuramochi M, Ohsawa R, et al. Optineurin defects cause TDP43-pathology with autophagic vacuolar formation[J]. Neurobiol Dis, 2021,148:105215. doi: 10.1016/j.nbd.2020.105215.
[7] Harding O, Evans CS, Ye J, et al. ALS- and FTD-associated missense mutations in TBK1 differentially disrupt mitophagy[J]. Proc Natl Acad Sci U S A, 2021, 118:e2025053118. doi: 10.1073/pnas.2025053118.
[8] Ye J, Cheung J, Gerbino V, et al. Effects of ALS-associated TANK binding kinase 1 mutations on protein-protein interactions and kinase activity[J]. Proc Natl Acad Sci U S A, 2019,116:24517-24526.
[9] Yilmaz R, Müller K, Brenner D, et al. SQSTM1/p62 variants in 486 patients with familial ALS from Germany and Sweden[J]. Neurobiol Aging, 2020,87:139. doi: 10.1016/j.neurobiolaging.2019.10.018.
[10] Ando T, Nakamura R, Kuru S, et al. The wide-ranging clinical and genetic features in Japanese families with valosin-containing protein proteinopathy[J]. Neurobiol Aging, 2021,100:120.e1-120.e6.
[11] Olesen MN, Wuolikainen A, Nilsson AC, et al. Inflammatory profiles relate to survival in subtypes of amyotro-phic lateral sclerosis[J]. Neurol Neuroimmunol Neuroinflamm, 2020,7:e697. doi: 10.1212/NXI.0000000000000697.
[12] Polverino A, Rucco R, Stillitano I, et al. In amyotrophic lateral sclerosis blood cytokines are altered, but do not correlate with changes in brain topology[J]. Brain Connect, 2020,10:411-421.
[13] Prado LGR, Rocha NP, de Souza LC, et al. Longitudinal assessment of clinical and inflammatory markers in patients with amyotrophic lateral sclerosis[J]. J Neurol Sci, 2018, 394:69-74.
[14] Martinez-Merino L, Iridoy M, Galbete A, et al. Evalua-tion of chitotriosidase and CC-chemokine ligand 18 as biomarkers of microglia activation in amyotrophic lateral sclerosis[J]. Neurodegener Dis, 2018,18:208-215.
[15] Pronto-Laborinho A, Pinto S, Gromicho M, et al. Interleukin-6 and amyotrophic lateral sclerosis[J]. J Neurol Sci,2019, 398:50-53.
[16] Tortelli R, Zecca C, Piccininni M, et al. plasma inflammatory cytokines are elevated in ALS[J]. Front Neurol, 2020, 552295. doi: 10.3389/fneur.2020.552295.
[17] Huang F, Zhu Y, Hsiao-Nakamoto J, et al. Longitudinal biomarkers in amyotrophic lateral sclerosis[J]. Ann Clin Transl Neurol, 2020, 7:1103-1116.
[18] Wosiski-Kuhn M, Robinson M, Strupe J, et al. IL6 receptor358Ala variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosis[J]. Neurol Neuroimmunol Neuroinflamm, 2019, 6:e631. doi: 10.1212/NXI.0000000000000631.
[19] Wosiski-Kuhn M, Caress JB, Cartwright MS, et al. Interleukin 6 (IL6) level is a biomarker for functional disease progression within IL6R358Ala variant groups in amyotrophic lateral sclerosis patients[J]. Amyotroph Lateral Scler Frontotemporal Degener, 2021, 22:248-259.
[20] Yuan S, Roos PM, Larsson SC. Interleukin-1 receptor antagonist, interleukin-2 receptor alpha subunit and amyotrophic lateral sclerosis[J]. Eur J Neurol, 2020, 27:1913-1917.
[21] Milligan C, Atassi N, Babu S, et al. Tocilizumab is safe and tolerable and reduces C-reactive protein concentra-tions in the plasma and cerebrospinal fluid of ALS patients[J]. Muscle Nerve, 2021, 64:309-320.
[22] Fournier CN, Schoenfeld D, Berry JD, et al. An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis[J]. Amyotroph Lateral Scler Frontotemporal Degener, 2018, 19:242-249.
[23] Camu W, Mickunas M, Veyrune JL, et al. Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): a phase 2a randomised, double-blind, placebo-controlled trial[J]. EBioMedicine, 2020, 59:102844. doi: 10.1016/j.ebiom.2020.102844.